RareCyte, Inc. is a life sciences company based in Seattle, Washington, that specializes in the development of liquid and tissue biopsy analysis platforms aimed at the detection of rare cells. Founded in 2009, RareCyte focuses on providing innovative technologies for the Life Sciences research, drug development, and diagnostic markets. The company offers a range of products, including sample preparation systems, staining kits, and automated fluorescence microscopy instruments. Its AccuCyte system is particularly notable for enabling the unbiased discovery and isolation of circulating tumor cells and circulating endothelial cells from whole blood. RareCyte's technologies are designed to address complex challenges in cancer and cardiovascular disease research, facilitating advancements in precision medicine and non-invasive prenatal testing.
Inipharm Inc. is a biopharmaceutical company based in Bellevue, Washington, established in 2018. The company specializes in discovering and developing therapies for severe liver diseases, particularly nonalcoholic steatohepatitis (NASH). Inipharm focuses on small-molecule drugs that target HSD17B13, a gene linked to various liver conditions. By modulating this gene's activity, Inipharm aims to reduce liver damage, inflammation, and fibrosis, addressing significant unmet medical needs in the treatment of liver diseases.
NodThera Limited is a biotechnology company based in Little Chesterford, United Kingdom, with additional facilities in Seattle, Washington, and Lexington, Massachusetts. Founded in 2016, the company specializes in researching and developing novel inhibitors of the NLRP3 inflammasome, a multi-protein complex involved in the body's immune response. NodThera aims to address a variety of inflammatory and neuroinflammatory diseases, including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. Through its innovative approach to inflammasome research, NodThera seeks to contribute to the advancement of therapeutic options for these conditions.
RareCyte, Inc. is a life sciences company based in Seattle, Washington, that specializes in the development of liquid and tissue biopsy analysis platforms aimed at the detection of rare cells. Founded in 2009, RareCyte focuses on providing innovative technologies for the Life Sciences research, drug development, and diagnostic markets. The company offers a range of products, including sample preparation systems, staining kits, and automated fluorescence microscopy instruments. Its AccuCyte system is particularly notable for enabling the unbiased discovery and isolation of circulating tumor cells and circulating endothelial cells from whole blood. RareCyte's technologies are designed to address complex challenges in cancer and cardiovascular disease research, facilitating advancements in precision medicine and non-invasive prenatal testing.
Impel NeuroPharma is a medical device company developing a novel drug delivery device that enables drugs to bypass the blood-brain barrier(BBB) using direct nose-to-brain delivery. It is focused on developing transformative therapies that unlock the full potential of therapeutic molecules for people living with CNS disorders with high unmet medical needs. The company was founded in 2008 and is headquartered in Seattle, Washington.
Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.
NodThera Limited is a biotechnology company based in Little Chesterford, United Kingdom, with additional facilities in Seattle, Washington, and Lexington, Massachusetts. Founded in 2016, the company specializes in researching and developing novel inhibitors of the NLRP3 inflammasome, a multi-protein complex involved in the body's immune response. NodThera aims to address a variety of inflammatory and neuroinflammatory diseases, including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. Through its innovative approach to inflammasome research, NodThera seeks to contribute to the advancement of therapeutic options for these conditions.
Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.
RareCyte, Inc. is a life sciences company based in Seattle, Washington, that specializes in the development of liquid and tissue biopsy analysis platforms aimed at the detection of rare cells. Founded in 2009, RareCyte focuses on providing innovative technologies for the Life Sciences research, drug development, and diagnostic markets. The company offers a range of products, including sample preparation systems, staining kits, and automated fluorescence microscopy instruments. Its AccuCyte system is particularly notable for enabling the unbiased discovery and isolation of circulating tumor cells and circulating endothelial cells from whole blood. RareCyte's technologies are designed to address complex challenges in cancer and cardiovascular disease research, facilitating advancements in precision medicine and non-invasive prenatal testing.
Impel NeuroPharma is a medical device company developing a novel drug delivery device that enables drugs to bypass the blood-brain barrier(BBB) using direct nose-to-brain delivery. It is focused on developing transformative therapies that unlock the full potential of therapeutic molecules for people living with CNS disorders with high unmet medical needs. The company was founded in 2008 and is headquartered in Seattle, Washington.
Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.
PhaseRx is a startup company based in Seattle focused on the delivery of siRNA and other macromolecular therapeutics. The Company has attracted top-tier venture investors and was founded by its President, Robert Overell, Patrick Stayton and Allan Hoffman of the University of Washington, Oliver Press of Fred Hutchinson Cancer Research Center, and Paul Johnson, the Company's Chief Scientific Officer. PhaseRx was conceived on the basis of using novel polymer technology to deliver siRNA. The Company believes the technology also has significant applications for the delivery of other macromolecular therapeutics.